Equities

Profile data is unavailable for this security.

About the company

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Performance Materials business provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.

  • Revenue in EUR (TTM)15.35bn
  • Net income in EUR1.12bn
  • Incorporated--
  • Employees53.05k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MRKX:GER since
announced
Transaction
value
Versum Materials IncAnnounced27 Feb 201927 Feb 2019Announced1.39%5.80bn
Data delayed at least 15 minutes, as of Aug 21 2019 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Recordati SpA1.40bn322.46m8.08bn4.14k25.067.4020.825.771.541.546.695.220.66882.084.98337,864.3015.4114.6419.4218.3070.2869.1023.0520.561.1222.380.402761.234.987.518.1818.509.4522.76
Shanghai Fosun Pharmaceutical (Group)3.31bn346.69m8.27bn28.25k24.792.37--2.501.071.0710.2311.210.383.377.01918,006.204.446.576.599.7757.7854.3811.7018.220.9381--0.408530.1134.4520.04-13.3311.3425.013.46
Merck KGaA15.35bn1.12bn12.33bn53.05k37.172.424.310.80332.577.9535.2540.370.40731.964.73296,888.603.014.544.015.9863.2766.097.3911.030.82536.130.39419.902.205.98-57.97-2.2814.485.64
UCB SA4.69bn652.00m13.20bn7.50k19.551.9713.492.823.473.5224.9334.420.45251.835.20625,216.806.555.008.316.4973.9071.7014.4712.520.887110.100.17744.362.258.135.3257.39-0.1751.66
Shionogi & Co Ltd3.00bn1.06bn15.63bn5.23k14.592.7216.045.21399.62399.621,129.652,144.110.47471.446.5767,728,260.0016.7713.2118.6715.0784.2877.7235.3226.766.21--0.001326.565.534.6521.9526.73-12.1115.36
Data as of Aug 21 2019. Currency figures normalised to Merck KGaA's reporting currency: Euro EUR
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.